- Home
- PEBK vs CGEN Comparison
PEBK vs CGEN Comparison
Compare PEBK & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEBK
- CGEN
- Stock Information
- Founded
- PEBK 1912
- CGEN 1993
- Country
- PEBK United States
- CGEN Israel
- Employees
- PEBK N/A
- CGEN N/A
- Industry
- PEBK Major Banks
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PEBK Finance
- CGEN Health Care
- Exchange
- PEBK Nasdaq
- CGEN Nasdaq
- Market Cap
- PEBK 155.1M
- CGEN 167.4M
- IPO Year
- PEBK N/A
- CGEN 2000
- Fundamental
- Price
- PEBK $31.68
- CGEN $1.41
- Analyst Decision
- PEBK
- CGEN
- Analyst Count
- PEBK 0
- CGEN 0
- Target Price
- PEBK N/A
- CGEN N/A
- AVG Volume (30 Days)
- PEBK 7.7K
- CGEN 208.5K
- Earning Date
- PEBK 10-20-2025
- CGEN 08-06-2025
- Dividend Yield
- PEBK 3.03%
- CGEN N/A
- EPS Growth
- PEBK 4.77
- CGEN N/A
- EPS
- PEBK 3.11
- CGEN N/A
- Revenue
- PEBK $84,131,000.00
- CGEN $22,144,000.00
- Revenue This Year
- PEBK N/A
- CGEN N/A
- Revenue Next Year
- PEBK N/A
- CGEN $159.40
- P/E Ratio
- PEBK $10.19
- CGEN N/A
- Revenue Growth
- PEBK 6.23
- CGEN N/A
- 52 Week Low
- PEBK $23.74
- CGEN $1.13
- 52 Week High
- PEBK $33.31
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- PEBK 62.45
- CGEN 40.44
- Support Level
- PEBK $31.21
- CGEN $1.35
- Resistance Level
- PEBK $31.78
- CGEN $1.50
- Average True Range (ATR)
- PEBK 0.90
- CGEN 0.06
- MACD
- PEBK 0.24
- CGEN -0.00
- Stochastic Oscillator
- PEBK 82.37
- CGEN 23.81
About PEBK Peoples Bancorp of North Carolina Inc.
Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.